top of page

Publications

SELECTED SCIENTIFIC PUBLICATIONS

Novel Anti-PD1 Predictive Signature and Functional Dendritic-Cell Biomarkers in Melanoma Identified with Systems Immunology

A 15-gene signature predicts anti-PD1 response in melanoma by capturing dendritic cell–T cell crosstalk.

image.png

In revision

Novel CRISPR-Cas9 BAP1 Knockout Pre-Clinical Tumor Model Recapitulates Human Melanoma Tumorigenesis and Immune Evolution

A new syngeneic mouse model replicates the immunosuppressive features of BAP1-deficient melanomas for preclinical immunotherapy testing.

image.png

In revision

TIMP-1 is an activator of MHC-I expression in myeloid dendritic cells with implications for tumor immunogenicity

TIMP-1 boosts dendritic cell function and CD8⁺ T cell responses.

image.png
image.png

Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion.

Some tumors block T cells. We review how to overcome this and improve immunotherapy.

image.png
image.png

Novel prognostication biomarker adipophilin reveals a metabolic shift in uveal melanoma and new therapeutic opportunities

BAP1 loss in uveal melanoma promotes immunosuppressive metabolic reprogramming, making PLIN2 a prognostic biomarker and therapeutic target.

image.png
image.png

Epigenetic control of CD1D expression as a mechanism of resistance to immune checkpoint therapy in poorly immunogenic melanomas

Study reveals that epigenetic changes affecting β2M and CD1D impair antigen presentation and contribute to immune checkpoint therapy resistance in metastatic melanoma.

image.png
image.png

Loss of BAP1 is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development

CyTOF analysis revealed that BAP1 loss in uveal melanoma promotes an immunosuppressive microenvironment through HLA-DR, CD38, and CD74

image.png
image.png

Blockade of MIF–CD74 signalling on macrophages and dendritic cells restores the antitumour immune response against metastatic melanoma

The C36L1 peptide reactivates immune cells that tumors shut down, helping the body fight back against metastatic melanoma."

image.png
image.png

A novel microtubule de-stabilizing complementarity-determining region C36L1 peptide displays antitumor activity against melanoma in vitro and in vivo

The C36L1 peptide enters melanoma cells, disrupts their internal structure, and blocks growth and spread, leading them to die.

image.png
image.png

Blockade of insulin-like growth factors increases efficacy of paclitaxel in metastatic breast cancer

Breast tumors use growth signals from immune cells to spread, but blocking these signals alongside chemotherapy greatly reduced cancer growth and metastasis.

image.png
image.png
image.png

β-Actin-binding CDR-H2 from Monoclonal Antibody C7 Induces Apoptosis in Several Human Tumor Cells and Is Protective against Metastatic Melanoma

The C7H2 peptide enters tumor cells, disrupts their internal skeleton, and triggers cell death, stopping melanoma growth and spread without harming healthy cells

image.png
image.png

A New Phage-Display Tumor-Homing Peptide Fused to Antiangiogenic Peptide Generates a Novel Bioactive Molecule with Antimelanoma Activity

A new peptide was designed to home in on melanoma blood vessels and block their growth signals, slowing tumor development and improving survival in mice

image.png
image.png

contact@carlosrogerio.com

​

Whatsapp: +358(0) 40 646 8080

  • White LinkedIn Icon
  • White Facebook Icon
  • White Twitter Icon
  • White Instagram Icon

©2025 by Carlos Rogerio Figueiredo. Powered and secured by Wix

bottom of page